Selank
Synthetic tuftsin-analog heptapeptide studied in Russia as an anxiolytic and nootropic, with reported effects on GABA, serotonin, and BDNF.
Reviewed by Mei Li, PhD, Chief Science Officer
Overview
Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a metabolically stabilized analog of tuftsin, a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) fragment of immunoglobulin G with reported immunomodulatory activity. Adding a Pro-Gly-Pro tail to the tuftsin core was intended to slow enzymatic degradation and extend the peptide's duration of action. Published research has examined Selank primarily as an anxiolytic and nootropic agent, with most of the human and preclinical literature originating in Russia. Clinical studies conducted there have evaluated it in generalized anxiety disorder, neurasthenia, and related conditions, sometimes in head-to-head comparisons with benzodiazepines such as medazepam. Reported findings describe anxiety-reducing effects alongside possible antiasthenic and cognitive effects, without the sedation and dependence associated with benzodiazepines in those trials. It is described as a registered prescription anxiolytic in Russia (and available in Ukrainian pharmacies) but is not FDA-approved and remains unscheduled and research-use-only in the United States. Outside of the Russian regulatory context, the body of independent, replicated human evidence remains limited.
Mechanism of action
Selank is proposed to act through several interacting pathways rather than a single receptor target, and much of the mechanistic detail comes from preclinical models. Reported effects include modulation of GABAergic neurotransmission, which investigators have linked to its benzodiazepine-like anxiolytic profile, along with reported modulation of serotonin and dopamine metabolism in anxiety-relevant brain regions. Preclinical studies have described changes in brain-derived neurotrophic factor (BDNF) expression in the rat hippocampus following intranasal administration, and gene-expression work has reported changes in genes involved in GABAergic signaling. As a tuftsin derivative, Selank has also been reported to retain immunomodulatory activity, with reported effects on interleukin-6 and the balance of T-helper cytokines. A frequently cited proposed mechanism is inhibition of enkephalin-degrading enzymes, which would stabilize endogenous enkephalins; some studies have reported increased leu-enkephalin stability alongside reduced anxiety measures. These mechanisms are largely characterized in animal and cell models and should not be read as established in humans.
What published research has examined
The published research base for Selank centers on anxiety and cognition. Russian clinical trials have examined it in generalized anxiety disorder, phobic-anxiety and somatoform disorders, and neurasthenia, including comparative studies against benzodiazepine anxiolytics that reported broadly comparable anxiety reduction with additional antiasthenic and mild psychostimulant effects. Preclinical and exploratory work has additionally investigated attention, working memory, and neuroprotection, as well as neuroimmune endpoints reflecting its tuftsin-derived immunomodulatory origins. Because most trials were relatively short (on the order of two weeks), intranasally administered, and conducted within a single national research tradition, the evidence for cognitive and immune applications is best characterized as preliminary and not independently replicated at scale in Western trials. None of these applications should be construed as an approved indication outside Russia.
Safety considerations in the literature
In the Russian clinical literature, Selank was generally described as well tolerated over the short intranasal courses studied, with the trials emphasizing an absence of the sedation, muscle relaxation, tolerance, and withdrawal typically reported with benzodiazepines. That said, the available safety data come largely from small, short-duration studies within one research ecosystem, so long-term safety, effects of chronic administration, and independent replication of the tolerability profile remain poorly characterized. Reported adverse effects in the literature have been described as generally mild, but comprehensive pharmacovigilance data comparable to FDA-approved drugs do not exist. Selank is not FDA-approved and is unscheduled and research-use-only in the United States; material sold outside a regulated pharmacy context carries the usual concerns about identity, purity, and sterility. This summary reflects observations reported in the research literature and is not medical guidance.
Key published studies
| Study | Journal | Year | Finding |
|---|---|---|---|
| Efficacy and possible mechanisms of action of a new peptide anxiolytic Selank in the therapy of generalized anxiety disorders and neurasthenia | Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova | 2008 | Human comparative trial reporting anxiolytic efficacy broadly similar to the benzodiazepine medazepam in GAD/neurasthenia, with added antiasthenic effects; clinical-level but small and single-center. |
| Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo | Doklady Biological Sciences | 2008 | Preclinical rodent study (Inozemtseva et al.) reporting changes in hippocampal BDNF expression after intranasal Selank; animal-level mechanistic evidence. |
| GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells | Frontiers in Pharmacology | 2017 | In vitro gene-expression study in the human IMR-32 neuroblastoma cell line linking Selank to GABAergic signaling pathways; cell-level evidence supporting its proposed anxiolytic mechanism. |
Regulatory status
Current status: Unscheduled / RUO. Not FDA approved. PepSense tracks FDA filings and updates this record as the regulatory picture changes. See the FDA PCAC tracker for the July 2026 vote and what happens next.